BSX · Business segments
Boston Scientific (BSX) revenue by segment
Where Boston Scientific’s revenue comes from, as reported in its SEC filings.
Latest quarter: June 30, 2026
Total revenue on the income statement: $5.44B.
Revenue by Geography
| Line | Revenue | Share |
|---|---|---|
| United States | $3.43B | 62.9% |
| Non-US | $2.02B | 37.1% |
Revenue by Segment
| Line | Revenue | Share |
|---|---|---|
| Cardiovascular | $3.62B | 66.6% |
| MedSurg | $1.82B | 33.4% |
Latest year: December 31, 2025
Total revenue on the income statement: $20.07B.
Revenue by Geography
| Line | Revenue | Share |
|---|---|---|
| United States | $12.86B | 64.1% |
| EMEA | $3.45B | 17.2% |
| Asia Pacific | $3.08B | 15.3% |
| Latin America and Canada | $678M | 3.4% |
Revenue by Segment
| Line | Revenue | Share |
|---|---|---|
| Cardiovascular | $13.25B | 66.0% |
| MedSurg | $6.82B | 34.0% |
Revenue by Product
| Line | Revenue | Share |
|---|---|---|
| Interventional Cardiology & Vascular Therapies | $4.64B | 23.1% |
| Electrophysiology (EP) | $3.33B | 16.6% |
| Global Endoscopy (Endo) Reporting Unit | $2.92B | 14.5% |
| Global Urology and Pelvic Health Reporting Unit | $2.71B | 13.5% |
| Cardiac Rhythm Management | $2.33B | 11.6% |
| Watchman | $1.96B | 9.8% |
| Global Neuromodulation (NM) Reporting Unit | $1.2B | 6.0% |
| Interventional Oncology and Embolization | $996M | 5.0% |
Reading notes
Share is each line’s part of that breakdown. Margin is the company’s reported segment operating income divided by that segment’s revenue. Companies define segment profit differently and may re-cut segments over time, so a company’s lines can differ between years. Breakdowns that do not add up to within 5% of reported revenue are left out.